The Team

Predicta is guided by a veteran leadership team with decades of commercialization experience across genomics, oncology, and diagnostics.

Francois Aguet, PhD

Francois Aguet, PhD

Head of Computational Biology

Doron Lipson, PhD

Doron Lipson, PhD

CTO

Valentina Nardi, MD

Valentina Nardi, MD

Pathologist

Thomas Mullen, PhD

Thomas Mullen, PhD

CLIA Lab Director

Timothy Brennan

Timothy Brennan

Head of Clinical Operations

Danielle Sookiasian

Danielle Sookiasian

Principal Scientist

Julian Hess

Julian Hess

Principal Computational Biologist

Svetlana Podsvirova

Svetlana Podsvirova

Senior Scientist

Geneva Young

Geneva Young

Senior Scientist

Molly Hurley

Molly Hurley

Business Development

The Board

Mara Aspinall

Mara Aspinall

Partner, Illumina Ventures

Jay Wohlgemuth, MD

Jay Wohlgemuth, MD

Independent, Former CMO Quest Diagnostics

Ann DeWitt, PhD

Ann DeWitt, PhD

Partner, Engine Ventures

Irene Ghobrial, MD

Irene Ghobrial, MD

Professor of Medicine, Dana Farber Cancer Institute, Harvard Medical School

Scientific Co-founders

Predicta was founded by the world’s leading cancer genomics and multiple myeloma researchers from the Broad Institute and Dana Farber Cancer Institute – many are physician scientists who see patients every day.

Kenneth Anderson, MD

Kenneth Anderson, MD

Professor of Medicine, Dana Farber Cancer Institute, Harvard Medical School, Co-founder of C4 Therapeutics

Irene Ghobrial, MD

Irene Ghobrial, MD

Professor of Medicine, Dana Farber Cancer Institute, Harvard Medical School

Gad Getz, PhD

Gad Getz, PhD

Professor of Pathology, Mass General, Harvard Medical School, Co-founder of the Broad Institute and Scorpion Therapeutics

Keith Flaherty, MD

Keith Flaherty, MD

Professor of Medicine, Mass General, Harvard Medical School, Founder of Loxo Oncology, Strata Oncology, Scorpion Therapeutics

Romanos Sklavenitis-Pistofidis, MD, PhD

Romanos Sklavenitis-Pistofidis, MD, PhD

Instructor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School

Predicta is backed by leading life sciences investors